PD-L1 as a biomarker of response to immune-checkpoint inhibitors
DB Doroshow, S Bhalla, MB Beasley… - Nature reviews Clinical …, 2021 - nature.com
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
The cancer–natural killer cell immunity cycle
ND Huntington, J Cursons, J Rautela - Nature Reviews Cancer, 2020 - nature.com
Immunotherapy with checkpoint blockade induces rapid and durable immune control of
cancer in some patients and has driven a monumental shift in cancer treatment. Neoantigen …
cancer in some patients and has driven a monumental shift in cancer treatment. Neoantigen …
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
JL Huo, YT Wang, WJ Fu, N Lu, ZS Liu - Frontiers in immunology, 2022 - frontiersin.org
LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …
superfamily, is confirmed to be expressed on activated immune cells, mainly including …
Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
[HTML][HTML] Emerging role of natural products in cancer immunotherapy
S Dong, X Guo, F Han, Z He, Y Wang - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Cancer immunotherapy has become a new generation of anti-tumor treatment, but its
indications still focus on several types of tumors that are sensitive to the immune system …
indications still focus on several types of tumors that are sensitive to the immune system …
Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review
S Tan, D Day, SJ Nicholls, E Segelov - Cardio Oncology, 2022 - jacc.org
Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …
The role of PD-1 in acute and chronic infection
JM Jubel, ZR Barbati, C Burger, DC Wirtz… - Frontiers in …, 2020 - frontiersin.org
PD-1 as an immune checkpoint molecule down-regulates T cell activity during immune
responses in order to prevent autoimmune tissue damage. In chronic infections or tumors …
responses in order to prevent autoimmune tissue damage. In chronic infections or tumors …
PD-L1 expression as a predictive biomarker in cancer immunotherapy
SP Patel, R Kurzrock - Molecular cancer therapeutics, 2015 - AACR
The resurgence of cancer immunotherapy stems from an improved understanding of the
tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising …
tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising …
Recent progresses in phototherapy‐synergized cancer immunotherapy
CW Ng, J Li, K Pu - Advanced Functional Materials, 2018 - Wiley Online Library
Cancer immunotherapy has recently gained much attention in the search of cancer cure due
to its ability to “train” the immune system in seeking out and removing residual tumor cells …
to its ability to “train” the immune system in seeking out and removing residual tumor cells …